Been watching the publicly traded home health companies space pretty closely lately, and there's actually some solid momentum building here. The whole outpatient and home healthcare sector is shifting faster than most people realize.

So here's what's driving this: aging population globally, rising healthcare costs pushing people toward cheaper alternatives, and honestly, AI is starting to make a real difference in how these services operate. The market was valued around $416 billion in 2024 and projections show it hitting nearly $750 billion by 2030. That's real growth potential.

The industry's had a rough couple years post-pandemic, but there's been steady recovery. What's interesting is the valuation picture right now - trading at 18.1X forward P/E versus the S&P at 22.9X. So you're not overpaying for exposure to this sector.

Let me break down four publicly traded home health companies worth paying attention to:

The Pennant Group (PNTG) has been crushing it. Their Q3 results showed strong revenue growth across home health, hospice, and senior living segments. Management's guiding for 33.5% revenue growth in 2025 and 22.3% earnings growth. That's the kind of momentum you want to see. Their ROE of 9.4% beats the industry average.

Encompass Health (EHC) is another one I'm tracking. They just opened a new rehabilitation hospital in Lake Worth and added capacity during the quarter. Revenue expected to grow 10.4% with earnings up 19.6%. What stands out is their ROE at 17.8% - significantly above industry average. These are publicly traded home health companies that are actually expanding.

DaVita (DVA) controls a huge chunk of the kidney care market globally. Their dialysis patient revenues are up, and they're opening new centers both domestically and internationally. More modest growth expectations (5.8% revenue, 8.7% earnings), but their earnings yield of 8.9% is solid relative to the industry's 5%.

Option Care Health (OPCH) focuses on home infusion services and reported strong Q3 results with robust revenue and bottom-line improvements. The consensus is looking for 12.9% revenue growth and 39.8% earnings growth. That earnings growth is notable. Their ROE of 17.9% also beats industry standards.

What's really happening here is that these publicly traded home health companies are benefiting from structural tailwinds - aging demographics, cost pressures on the healthcare system, and technology adoption accelerating. The staffing challenges are real though, so execution matters.

If you're looking at the space, the valuation looks reasonable compared to broader market multiples, and the growth runway seems legitimate given industry dynamics. Worth keeping on your radar if you're building healthcare exposure.